Skip to main content
NCD 190.13 · version 1 · Laboratory NCD

NCD 190.13: Human Immunodeficiency Virus (HIV) Testing (Prognosis Including Monitoring)

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.13

Benefit category
Diagnostic Laboratory Tests
Effective date
11/25/2002
Implemented 01/01/2003
Transmittal
Transmittal 17
Versions published
1
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
22 covered ICD-10
233 non-covered

TL;DR

NCD 190.13 sets Medicare's national policy for human immunodeficiency virus (hiv) testing (prognosis including monitoring) under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. • A plasma HIV RNA baseline level may be medically necessary in any patient with confirmed HIV infection. As a laboratory NCD it carries a national ICD-10 edit list: 22 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 2 procedure codes.

Item or service described

HIV quantification is achieved through the use of a number of different assays which measure the amount of circulating viral RNA. Assays vary both in methods used to detect viral RNA as well as in ability to detect viral levels at lower limits. However, all employ some type of nucleic acid amplification technique to enhance sensitivity, and results are expressed as the HIV copy number.

Quantification assays of HIV plasma RNA are used prognostically to assess relative risk for disease progression and predict time to death, as well as to assess efficacy of antiretroviral therapies over time.

HIV quantification is often performed together with CD4+ T cell counts which provide information on extent of HIV induced immune system damage already incurred.

Indications and limitations of coverage

Indications

• A plasma HIV RNA baseline level may be medically necessary in any patient with confirmed HIV infection.

• Regular periodic measurement of plasma HIV RNA levels may be medically necessary to determine risk for disease progression in an HIV-infected individual and to determine when to initiate or modify antiretroviral treatment regimens.

• In clinical situations where the risk of HIV infection is significant and initiation of therapy is anticipated, a baseline HIV quantification may be performed. These situations include:

• Persistence of borderline or equivocal serologic reactivity in an at-risk individual.

• Signs and symptoms of acute retroviral syndrome characterized by fever, malaise, lymphadenopathy and rash in an at-risk individual.

Limitations

• Viral quantification may be appropriate for prognostic use including baseline determination, periodic monitoring, and monitoring of response to therapy. Use as a diagnostic test method is not indicated.

• Measurement of plasma HIV RNA levels should be performed at the time of establishment of an HIV infection diagnosis. For an accurate baseline, 2 specimens in a 2-week period are appropriate.

• For prognosis including anti-retroviral therapy monitoring, regular, periodic measurements are appropriate. The frequency of viral load testing should be consistent with the most current Centers for Disease Control and Prevention guidelines for use of anti-retroviral agents in adults and adolescents or pediatrics.

• Because differences in absolute HIV copy number are known to occur using different assays, plasma HIV RNA levels should be measured by the same analytical method. A change in assay method may necessitate re-establishment of a baseline.

• Nucleic acid quantification techniques are representative of rapidly emerging and evolving new technologies. As such, users are advised to remain current on FDA-approval status.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.13 version 1. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 22 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.

2 procedure codes are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.13
CodeCode set
87536CPT (descriptor licensed by AMA)
87539CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 2 of the 2 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $58.62 to $85.10, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.13 edits, October 2026
CodeCLFS amountWith QWPricing
87536$85.10—national payment amount
87539$58.62—national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

The first 22 of 22 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.13 (sample)
ICD-10-CMDescriptionEffective
B20Human immunodeficiency virus [HIV] disease2015-10-01
B97.35Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere2015-10-01
O98.411Viral hepatitis complicating pregnancy, first trimester2015-10-01
O98.412Viral hepatitis complicating pregnancy, second trimester2015-10-01
O98.413Viral hepatitis complicating pregnancy, third trimester2015-10-01
O98.419Viral hepatitis complicating pregnancy, unspecified trimester2015-10-01
O98.42Viral hepatitis complicating childbirth2015-10-01
O98.43Viral hepatitis complicating the puerperium2015-10-01
O98.511Other viral diseases complicating pregnancy, first trimester2015-10-01
O98.512Other viral diseases complicating pregnancy, second trimester2015-10-01
O98.513Other viral diseases complicating pregnancy, third trimester2015-10-01
O98.519Other viral diseases complicating pregnancy, unspecified trimester2015-10-01
O98.52Other viral diseases complicating childbirth2015-10-01
O98.53Other viral diseases complicating the puerperium2015-10-01
O98.711Human immunodeficiency virus [HIV] disease complicating pregnancy, first trimester2015-10-01
O98.712Human immunodeficiency virus [HIV] disease complicating pregnancy, second trimester2015-10-01
O98.713Human immunodeficiency virus [HIV] disease complicating pregnancy, third trimester2015-10-01
O98.719Human immunodeficiency virus [HIV] disease complicating pregnancy, unspecified trimester2015-10-01
O98.72Human immunodeficiency virus [HIV] disease complicating childbirth2015-10-01
O98.73Human immunodeficiency virus [HIV] disease complicating the puerperium2015-10-01
R75Inconclusive laboratory evidence of human immunodeficiency virus [HIV]2015-10-01
Z21Asymptomatic human immunodeficiency virus [HIV] infection status2015-10-01

233 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.13 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release made no change to this NCD's ICD-10-CM list: no code was added, removed or given a new result against January 2026.

Codes on this NCD's list by release: October 2025: 255 · January 2026: 255 · October 2026: 255. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Revision history

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.13

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.13

What does NCD 190.13 cover?

• A plasma HIV RNA baseline level may be medically necessary in any patient with confirmed HIV infection. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.13 take effect?

The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.

Does a Local Coverage Determination override NCD 190.13?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.13?

The October 2026 laboratory NCD edit list contains 22 ICD-10-CM codes that support human immunodeficiency virus (hiv) testing (prognosis including monitoring) (for example B20 Human immunodeficiency virus [HIV] disease; B97.35 Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere; O98.411 Viral hepatitis complicating pregnancy, first trimester) and 233 codes that deny. The list applies to 87536, 87539.

How often does the lab NCD code list for 190.13 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.